clinical trial · NCT03114865
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·phase2·active not recruiting·n = 44
Acute Lymphoblastic LeukemiaB-cell Non Hodgkin LymphomaPre B-Cell Acute Lymphoblastic LeukaemiaBlinatumomab 9ugBlinatumomab 28 ugBlinatumomabDexamethasone
brief summary
The investigators primary objective is to determine the safety and toxicity of incorporating blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance setting for patients with CD19+-B-cell malignancies (Acute Lymphoblastic Leukemia \[ALL\], Non-Hodgkin's Lymphoma \[NHL\]).
started
Sep 5, 2017
primary completion
Dec 30, 2026
completion
Dec 30, 2026
last updated
Oct 22, 2026
official title
A Phase IB/II Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol